arrow
A

Ali Alkan

Vrije Universiteit Brussel
H指数:15
被引数:929

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

国际IV期实地研究以验证欧洲癌症研究与治疗组织问卷用于评估癌症幸存者的健康相关生活质量:EORTC QLQ-SURV100

2026-08-010
PRE
Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer

血清癌胚抗原水平在转移性非小细胞肺癌分子亚型中的分布及其临床和预后意义

2026-04-090
OA
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

局部晚期直肠癌中总新辅助疗法的真实世界有效性:一项多中心回顾性研究

2026-03-230
OAAI
Survival outcomes and recurrence patterns of early-stage HER2-positive breast cancer patients on adjuvant T-DM1 treatment: Turkish Oncology Group (TOG) Study

早期HER2阳性乳腺癌患者接受辅助T-DM1治疗的生存结局与复发模式:土耳其肿瘤学组(TOG)研究

2025-12-010
PRE
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

靶向疗法在肺鳞状细胞癌转移中的疗效:一项土耳其肿瘤学组多中心研究

2025-12-010
PRE
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study (vol 14, 23556, 2024)
2025-03-180
OAAI
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

黑色素瘤的辅助和一线转移治疗的预后因素和结果土耳其肿瘤学组研究

2025-01-250
OAAI
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
2024-11-300
OAAI
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

早期三阴性乳腺癌中Her2状态对预后的影响:一项土耳其肿瘤学组(TOG)研究

2024-10-090
OA
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

细胞周期蛋白依赖性激酶抑制剂后依维莫司加激素治疗的疗效; 现实生活经验,TOG研究

2024-08-090
PRE